Pharmacological targeting of host chaperones protects from pertussis toxin in vitro and in vivo.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 03 2021
Historique:
received: 03 08 2020
accepted: 16 02 2021
entrez: 9 3 2021
pubmed: 10 3 2021
medline: 15 12 2021
Statut: epublish

Résumé

Whooping cough is caused by Bordetella pertussis that releases pertussis toxin (PT) which comprises enzyme A-subunit PTS1 and binding/transport B-subunit. After receptor-mediated endocytosis, PT reaches the endoplasmic reticulum from where unfolded PTS1 is transported to the cytosol. PTS1 ADP-ribosylates G-protein α-subunits resulting in increased cAMP signaling. Here, a role of target cell chaperones Hsp90, Hsp70, cyclophilins and FK506-binding proteins for cytosolic PTS1-uptake is demonstrated. PTS1 specifically and directly interacts with chaperones in vitro and in cells. Specific pharmacological chaperone inhibition protects CHO-K1, human primary airway basal cells and a fully differentiated airway epithelium from PT-intoxication by reducing intracellular PTS1-amounts without affecting cell binding or enzyme activity. PT is internalized by human airway epithelium secretory but not ciliated cells and leads to increase of apical surface liquid. Cyclophilin-inhibitors reduced leukocytosis in infant mouse model of pertussis, indicating their promising potential for developing novel therapeutic strategies against whooping cough.

Identifiants

pubmed: 33686161
doi: 10.1038/s41598-021-84817-2
pii: 10.1038/s41598-021-84817-2
pmc: PMC7940712
doi:

Substances chimiques

Enzyme Inhibitors 0
Molecular Chaperones 0
Pertussis Toxin EC 2.4.2.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5429

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI141372
Pays : United States

Références

Agents Actions. 1976 Jul;6(4):468-75
pubmed: 8969
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004404
pubmed: 17636756
Anal Chem. 2013 May 7;85(9):4247-50
pubmed: 23560702
Curr Opin Pharmacol. 2019 Aug;47:126-132
pubmed: 31039505
Eur J Cell Biol. 1997 May;73(1):40-8
pubmed: 9174670
Cell. 2007 Oct 5;131(1):121-35
pubmed: 17923092
Front Immunol. 2019 Dec 13;10:2869
pubmed: 31921136
Biochim Biophys Acta. 2015 Oct;1850(10):2005-16
pubmed: 25445709
Biochemistry. 2006 Nov 21;45(46):13734-40
pubmed: 17105192
Exp Biol Med (Maywood). 2003 Feb;228(2):111-33
pubmed: 12563018
Biomolecules. 2018 Dec 14;8(4):
pubmed: 30558250
Cell Microbiol. 2008 May;10(5):1130-9
pubmed: 18201245
Cell Microbiol. 2009 May;11(5):780-95
pubmed: 19159389
Infect Immun. 2008 Nov;76(11):5139-48
pubmed: 18765723
Pediatr Infect Dis. 1984 Sep-Oct;3(5):467-86
pubmed: 6093069
Cell. 1989 Mar 10;56(5):801-13
pubmed: 2647301
Eukaryot Cell. 2005 May;4(5):849-60
pubmed: 15879519
Proc Biol Sci. 2016 Jan 13;283(1822):
pubmed: 26763701
Cell Microbiol. 2012 Aug;14(8):1193-205
pubmed: 22420783
Vaccine. 2011 Mar 16;29(13):2355-6
pubmed: 21129396
Biochemistry. 1982 Oct 26;21(22):5516-22
pubmed: 6293544
Infect Immun. 2014 Oct;82(10):4212-21
pubmed: 25069981
APMIS. 2010 Dec;118(12):968-72
pubmed: 21091778
J Mol Biol. 1996 May 17;258(4):661-71
pubmed: 8637000
Infect Immun. 2016 Nov 18;84(12):3388-3398
pubmed: 27647866
Toxins (Basel). 2018 May 01;10(5):
pubmed: 29723951
J Biol Chem. 2014 Nov 28;289(48):33644-54
pubmed: 25320090
Cell Microbiol. 2019 Oct;21(10):e13074
pubmed: 31231933
Cell Microbiol. 2011 Mar;13(3):359-73
pubmed: 20946244
J Immunol. 1985 Dec;135(6):4135-43
pubmed: 2999238
ACS Sens. 2020 Nov 25;5(11):3438-3448
pubmed: 33147407
J Biol Chem. 2003 Aug 22;278(34):32266-74
pubmed: 12805360
Infect Immun. 1983 Jun;40(3):1198-203
pubmed: 6682833
Infect Immun. 2007 Jun;75(6):2946-53
pubmed: 17420233
Cell Microbiol. 2010 Feb;12(2):233-47
pubmed: 19840027
Structure. 1994 Jan 15;2(1):45-57
pubmed: 8075982
Biomed J. 2013 May-Jun;36(3):106-17
pubmed: 23806880
J Mol Biol. 2015 Mar 27;427(6 Pt A):1224-38
pubmed: 25058685
Clin Microbiol Rev. 2005 Apr;18(2):326-82
pubmed: 15831828
Physiol Rev. 2019 Jan 1;99(1):707-738
pubmed: 30516439
Front Pharmacol. 2018 Nov 13;9:1287
pubmed: 30483129
Pathog Dis. 2016 Aug;74(6):
pubmed: 27369899
Sci Rep. 2017 Apr 4;7(1):613
pubmed: 28377614
J Biol Chem. 1983 Feb 25;258(4):2072-5
pubmed: 6296122
Infect Immun. 2011 Oct;79(10):3913-21
pubmed: 21768281
Infect Immun. 2004 May;72(5):3066-8
pubmed: 15102823
FEBS J. 2011 Dec;278(23):4668-82
pubmed: 21740523
J Biol Chem. 2019 Aug 9;294(32):12122-12131
pubmed: 31221799
Curr Opin Infect Dis. 2016 Jun;29(3):287-94
pubmed: 26906206
ACS Infect Dis. 2020 Apr 10;6(4):588-602
pubmed: 31899865
Antimicrob Agents Chemother. 1994 Aug;38(8):1763-72
pubmed: 7527198
Infect Immun. 1989 Nov;57(11):3324-30
pubmed: 2478471
Sci Rep. 2017 Jun 2;7(1):2724
pubmed: 28578412
Toxins (Basel). 2019 Jun 27;11(7):
pubmed: 31252532
Infect Immun. 2017 Oct 18;85(11):
pubmed: 28784932
Proc Natl Acad Sci U S A. 1982 May;79(10):3129-33
pubmed: 6954463
Sci Rep. 2016 Feb 03;6:20301
pubmed: 26839186
J Clin Invest. 2005 Dec;115(12):3594-601
pubmed: 16294220
Infect Immun. 1995 Mar;63(3):825-32
pubmed: 7868253
Toxins (Basel). 2019 Jul 17;11(7):
pubmed: 31319496
Cell. 2005 Mar 11;120(5):715-27
pubmed: 15766533
Pathog Dis. 2016 Oct;74(7):
pubmed: 27609461
Methods Mol Med. 2005;107:183-206
pubmed: 15492373
Cell. 1991 Aug 23;66(4):807-15
pubmed: 1715244
Pediatrics. 1997 Dec;100(6):E10
pubmed: 9382911
J Biol Chem. 2010 Oct 8;285(41):31261-7
pubmed: 20667832
Curr Top Microbiol Immunol. 2017;406:163-198
pubmed: 27197646
J Biol Chem. 1996 Feb 9;271(6):2961-5
pubmed: 8621687
Am J Respir Crit Care Med. 2019 Mar 15;199(6):715-727
pubmed: 30352166
Clin Microbiol Rev. 2016 Jul;29(3):449-86
pubmed: 27029594
Pathog Dis. 2015 Nov;73(8):ftv073
pubmed: 26394801

Auteurs

Katharina Ernst (K)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany. katharina.ernst@uni-ulm.de.

Ann-Katrin Mittler (AK)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Veronika Winkelmann (V)

Institute of General Physiology, University of Ulm, Ulm, Germany.

Carolin Kling (C)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Nina Eberhardt (N)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Anna Anastasia (A)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Michael Sonnabend (M)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Robin Lochbaum (R)

Institute of General Physiology, University of Ulm, Ulm, Germany.

Jan Wirsching (J)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Moona Sakari (M)

Institute of Biomedicine, Research Unit for Infection and Immunity, University of Turku, Turku, Finland.

Arto T Pulliainen (AT)

Institute of Biomedicine, Research Unit for Infection and Immunity, University of Turku, Turku, Finland.

Ciaran Skerry (C)

Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.

Nicholas H Carbonetti (NH)

Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.

Manfred Frick (M)

Institute of General Physiology, University of Ulm, Ulm, Germany.

Holger Barth (H)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany. holger.barth@uni-ulm.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH